Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II
SF Zhou - Clinical pharmacokinetics, 2009 - Springer
Part I of this article discussed the potential functional importance of genetic mutations and
alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 …
alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 …
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
RJ Bertz, GR Granneman - Clinical pharmacokinetics, 1997 - Springer
This article reviews the information available to assist pharmacokineticists in the prediction
of metabolic drug interactions. Significant advances in this area have been made in the last …
of metabolic drug interactions. Significant advances in this area have been made in the last …
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
SJ Gardiner, EJ Begg - Pharmacological reviews, 2006 - ASPET
The application of pharmacogenetics holds great promise for individualized therapy.
However, it has little clinical reality at present, despite many claims. The main problem is that …
However, it has little clinical reality at present, despite many claims. The main problem is that …
Gender effects in pharmacokinetics and pharmacodynamics
RZ Harris, LZ Benet, JB Schwartz - Drugs, 1995 - Springer
There are a number of examples of sex differences in drug pharmacokinetics and
pharmacodynamics. Recent advances in the characterisation of specific isozymes involved …
pharmacodynamics. Recent advances in the characterisation of specific isozymes involved …
Clinical importance of hepatic cytochrome P450 in drug metabolism
M Spatzenegger, W Jaeger - Drug metabolism reviews, 1995 - Taylor & Francis
Hepatic drug metabolism is crucial for the elimination of many therapeutic drugs. Among the
most important drug-metabolizing enzymes is cytochrome P450, a group of …
most important drug-metabolizing enzymes is cytochrome P450, a group of …
Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications
MI Wilde, A Markham - Drugs, 1996 - Springer
Synopsis The use of ondansetron, a selective serotonin 5-HT 3 receptor antagonist, is well
established in patients with nausea and vomiting associated with cancer chemotherapy …
established in patients with nausea and vomiting associated with cancer chemotherapy …
The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of …
Background Some patients treated with ondansetron for postoperative nausea and vomiting
do not respond to therapy. One possible mechanism for this failure is ultrarapid drug …
do not respond to therapy. One possible mechanism for this failure is ultrarapid drug …
Ondansetron clinical pharmacokinetics
F Roila, A Del Favero - Clinical pharmacokinetics, 1995 - Springer
Ondansetron is a potent and highly selective serotonin 5-HT 3-receptor antagonist which
has demonstrated important antiemetic activity and good tolerability in the prevention of …
has demonstrated important antiemetic activity and good tolerability in the prevention of …
Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator
U Ezuruike, M Zhang, A Pansari… - CPT …, 2022 - Wiley Online Library
Abstract The Simcyp Simulator is a software platform for population physiologically‐based
pharmacokinetic (PBPK) modeling and simulation. It links in vitro data to in vivo absorption …
pharmacokinetic (PBPK) modeling and simulation. It links in vitro data to in vivo absorption …
Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development
Human cytochrome P450 1A2 (CYP1A2) is one of the major CYPs in the liver (&sim13%)
and metabolizes about 20% of clinically used drugs. CYP1A2 is a 515-residue protein with a …
and metabolizes about 20% of clinically used drugs. CYP1A2 is a 515-residue protein with a …